These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 24354513)

  • 1. Expression of hypoxia-inducible factor-1α, vascular endothelial growth factor and prolyl hydroxylase domain protein 2 in cutaneous squamous cell carcinoma and precursor lesions and their relationship with histological stages and clinical features.
    An X; Xu G; Yang L; Wang Y; Li Y; McHepange UO; Shen G; Tu Y; Tao J
    J Dermatol; 2014 Jan; 41(1):76-83. PubMed ID: 24354513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-21 contributes to renal protection by targeting prolyl hydroxylase domain protein 2 in delayed ischaemic preconditioning.
    Jiao X; Xu X; Fang Y; Zhang H; Liang M; Teng J; Ding X
    Nephrology (Carlton); 2017 May; 22(5):366-373. PubMed ID: 27030384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression and nuclear translocation of hypoxia-inducible factor prolyl hydroxylase PHD2 in head and neck squamous cell carcinoma is associated with tumor aggressiveness.
    Jokilehto T; Rantanen K; Luukkaa M; Heikkinen P; Grenman R; Minn H; Kronqvist P; Jaakkola PM
    Clin Cancer Res; 2006 Feb; 12(4):1080-7. PubMed ID: 16489060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential expression of ezrin in epithelial skin tumors: cytoplasmic ezrin immunoreactivity in squamous cell carcinoma.
    Park HR; Min SK; Min K; Jun SY; Seo J; Kim KH; Choi J
    Int J Dermatol; 2010 Jan; 49(1):48-52. PubMed ID: 20465611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolyl hydroxylase domain 2 deficiency promotes skeletal muscle fiber-type transition via a calcineurin/NFATc1-dependent pathway.
    Shin J; Nunomiya A; Kitajima Y; Dan T; Miyata T; Nagatomi R
    Skelet Muscle; 2016; 6():5. PubMed ID: 26949511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gambogic acid inhibits angiogenesis through inhibiting PHD2-VHL-HIF-1α pathway.
    Lu N; Hui H; Yang H; Zhao K; Chen Y; You QD; Guo QL
    Eur J Pharm Sci; 2013 May; 49(2):220-6. PubMed ID: 23501055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression of hypoxia-inducible factor-1alpha and vessel endothelial growth factor in esophageal squamous cell carcinoma and clinico-pathological significance thereof].
    Yu ZT; Zhao HF; Shang XB
    Zhonghua Yi Xue Za Zhi; 2008 Sep; 88(35):2465-9. PubMed ID: 19080625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CCR10 and CCL27 are overexpressed in cutaneous squamous cell carcinoma.
    Kai H; Kadono T; Kakinuma T; Tomita M; Ohmatsu H; Asano Y; Tada Y; Sugaya M; Sato S
    Pathol Res Pract; 2011 Jan; 207(1):43-8. PubMed ID: 21144674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression of promyelocytic leukaemia protein in Bowen's disease, skin squamous cell carcinoma and basal cell carcinoma].
    Wang Q; Ma H; Wang S; Ma Y; Zou X; Li R
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jul; 33(7):1075-7. PubMed ID: 23895857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased activation of the hypoxia-inducible factor pathway in varicose veins.
    Lim CS; Kiriakidis S; Paleolog EM; Davies AH
    J Vasc Surg; 2012 May; 55(5):1427-39. PubMed ID: 22277691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha with progression of keratinocytic neoplasms.
    Lining X; Uchi H; Hayashida S; Tsuji G; Kido M; Nakahara T; Takeuchi S; Takahara M; Moroi Y; Furue M
    J Dermatol Sci; 2009 Nov; 56(2):135-6. PubMed ID: 19660915
    [No Abstract]   [Full Text] [Related]  

  • 12. Cyclin A and beta-catenin expression in actinic keratosis, Bowen's disease and invasive squamous cell carcinoma of the skin.
    Brasanac D; Boricic I; Todorovic V; Tomanovic N; Radojevic S
    Br J Dermatol; 2005 Dec; 153(6):1166-75. PubMed ID: 16307653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of angiogenesis through stabilization of hypoxia-inducible factor-1 by silencing prolyl hydroxylase domain-2 gene.
    Wu S; Nishiyama N; Kano MR; Morishita Y; Miyazono K; Itaka K; Chung UI; Kataoka K
    Mol Ther; 2008 Jul; 16(7):1227-34. PubMed ID: 18500250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia-inducible factors in the first trimester human lung.
    Groenman F; Rutter M; Caniggia I; Tibboel D; Post M
    J Histochem Cytochem; 2007 Apr; 55(4):355-63. PubMed ID: 17189520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolyl hydroxylase domain 2 protein suppresses hypoxia-induced endothelial cell proliferation.
    Takeda K; Fong GH
    Hypertension; 2007 Jan; 49(1):178-84. PubMed ID: 17101841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RUNX3 inhibits hypoxia-inducible factor-1α protein stability by interacting with prolyl hydroxylases in gastric cancer cells.
    Lee SH; Bae SC; Kim KW; Lee YM
    Oncogene; 2014 Mar; 33(11):1458-67. PubMed ID: 23542169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of L-type amino acid transporter 1 in various skin lesions.
    Hirano K; Uno K; Kuwabara H; Kojima K; Ohno S; Sakurai H; Kamma H; Kurata A
    Pathol Res Pract; 2014 Oct; 210(10):634-9. PubMed ID: 24939142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipophilic modification enhances anti-colitic properties of rosmarinic acid by potentiating its HIF-prolyl hydroxylases inhibitory activity.
    Jeong S; Park H; Hong S; Yum S; Kim W; Jung Y
    Eur J Pharmacol; 2015 Jan; 747():114-22. PubMed ID: 25483211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-density lipoproteins augment hypoxia-induced angiogenesis via regulation of post-translational modulation of hypoxia-inducible factor 1α.
    Tan JT; Prosser HC; Vanags LZ; Monger SA; Ng MK; Bursill CA
    FASEB J; 2014 Jan; 28(1):206-17. PubMed ID: 24022405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of
    Li XY; Wu CH; Yan YJ; Wang DH; Wang MJ; Hou ZW
    Zhongguo Zhen Jiu; 2022 Nov; 42(11):1278-84. PubMed ID: 36397226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.